Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

CHICAGO, IL / ACCESS Newswire / September 28, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that the contract manufacturing ("CMO") pipeline of its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has surpassed $20 million in implied revenue over the life of the underlying agreements, representing over $18 million in implied gross profit at gross margins of over 90%, as the production pipeline reaches a record of more than 32.7 million units.

The CMO pipeline is spread across agreements with an average duration of approximately four years, with certain contracts extending up to ten years. Implied revenue and implied gross profit are therefore aggregate amounts realized over that period as orders are placed, rather than annual figures. On that basis the current pipeline equates to approximately $5 million in implied annual revenue and approximately $4.5 million in implied annual gross profit, reflecting production volumes secured to date. As the pipeline continues to grow, the division is working toward its target of over $10 million in recurring annual gross profit at full capacity. A Record CMO Pipeline, Growing Rapidly